Yuhan Chemical
South Korea Updated 9 July 2026
Yuhan Chemical is an API manufacturer based in South Korea. It holds 2 active US drug master files across a filed portfolio of 5 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 February 2025 as VAI.
2
registered plants
2 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 28 February 2025 VAI US FDA
- 12 January 2024 VAI US FDA
- 17 January 2020 VAI US FDA
- 1 November 2018 NAI US FDA
- 22 September 2017 VAI US FDA
- 4 December 2015 VAI US FDA
- 27 June 2014 NAI US FDA
- 8 November 2012 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| South, South Korea | 3008853591 |
| South, South Korea | 3004015296 |
What they file, and where
| Molecule | Regulators | Docs |
| Emtricitabine | SFDA (Saudi Arabia) | 1 |
| Piperacillin | US FDA | 1 |
| Ribavirin | US FDA | 1 |
| Velpatasvir | SFDA (Saudi Arabia) | 1 |
| Voxilaprevir | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | None | 2 |
Comparing suppliers?
Choose your molecules and target markets. Yuhan Chemical comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 28 February 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates